WO2002024230A1 - Solid preparations - Google Patents

Solid preparations Download PDF

Info

Publication number
WO2002024230A1
WO2002024230A1 PCT/JP2001/008264 JP0108264W WO0224230A1 WO 2002024230 A1 WO2002024230 A1 WO 2002024230A1 JP 0108264 W JP0108264 W JP 0108264W WO 0224230 A1 WO0224230 A1 WO 0224230A1
Authority
WO
WIPO (PCT)
Prior art keywords
solid preparations
active substance
physiologically active
granules
cellulose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2001/008264
Other languages
English (en)
French (fr)
Inventor
Yoshinori Nakano
Shuji Yoneyama
Masashi Ochi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Priority to US10/380,725 priority Critical patent/US20040034039A1/en
Priority to AU2001288102A priority patent/AU2001288102A1/en
Priority to EP01967797A priority patent/EP1319409A4/en
Priority to CA002423329A priority patent/CA2423329A1/en
Publication of WO2002024230A1 publication Critical patent/WO2002024230A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/JP2001/008264 2000-09-22 2001-09-21 Solid preparations Ceased WO2002024230A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US10/380,725 US20040034039A1 (en) 2000-09-22 2001-09-21 Solid preparations
AU2001288102A AU2001288102A1 (en) 2000-09-22 2001-09-21 Solid preparations
EP01967797A EP1319409A4 (en) 2000-09-22 2001-09-21 SOLID PREPARATIONS
CA002423329A CA2423329A1 (en) 2000-09-22 2001-09-21 Solid preparations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000-289345 2000-09-22
JP2000289345 2000-09-22

Publications (1)

Publication Number Publication Date
WO2002024230A1 true WO2002024230A1 (en) 2002-03-28

Family

ID=18772770

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/008264 Ceased WO2002024230A1 (en) 2000-09-22 2001-09-21 Solid preparations

Country Status (5)

Country Link
US (1) US20040034039A1 (ja)
EP (1) EP1319409A4 (ja)
AU (1) AU2001288102A1 (ja)
CA (1) CA2423329A1 (ja)
WO (1) WO2002024230A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003064429A1 (en) * 2002-01-30 2003-08-07 Takeda Chemical Industries, Ltd. Thienopyrimidines, process for preparing the same and use thereof

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100891887B1 (ko) 2001-01-29 2009-04-03 시오노기세이야쿠가부시키가이샤 5-메틸-1-페닐-2-(1h)-피리돈을 활성 성분으로서 함유하는의약 제제
US7300935B2 (en) 2003-01-29 2007-11-27 Takeda Pharmaceutical Company Thienopyrimidine compounds and use thereof
KR100882156B1 (ko) 2003-08-08 2009-02-06 아지노모토 가부시키가이샤 나테글리니드 함유 제제
ES2655435T3 (es) 2003-09-12 2018-02-20 Amgen Inc. Formulación de disolución rápida de cinacalcet
US8513261B2 (en) * 2009-03-13 2013-08-20 Toyama Chemical Co., Ltd. Tablet and granulated powder containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995022981A1 (en) * 1994-02-24 1995-08-31 Nippon Chemiphar Co., Ltd. Oral synthetic peptide preparation
WO1997040846A1 (en) * 1996-04-30 1997-11-06 Takeda Chemical Industries, Ltd. COMBINED USE OF GnRH AGONIST AND ANTAGONIST
JPH1045619A (ja) * 1996-07-31 1998-02-17 Kaken Pharmaceut Co Ltd 成長ホルモン分泌促進ペプチド含有経口製剤
WO2000000493A1 (en) * 1998-06-26 2000-01-06 Takeda Chemical Industries, Ltd. Thienopyridine compounds, their production and use
WO2000056739A1 (en) * 1999-03-24 2000-09-28 Takeda Chemical Industries, Ltd. Thienopyrimidine compounds, their production and use
WO2001012193A1 (en) * 1999-08-16 2001-02-22 Schering Aktiengesellschaft Pharmaceutical agent comprising a benzamide derivative as active ingredient

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5921613A (ja) * 1982-07-28 1984-02-03 Takeda Chem Ind Ltd 直腸投与製剤
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US5629016A (en) * 1991-01-30 1997-05-13 Glaxo Wellcome Inc. Water-dispersible tablets
US5155115A (en) * 1991-03-12 1992-10-13 Kyowa Hakko Kogyo Co., Ltd. Thienopyridine derivatives
TW449600B (en) * 1994-04-19 2001-08-11 Takeda Chemical Industries Ltd Condensed-ring thiophene derivatives, their production and use
MX9706062A (es) * 1995-02-08 1997-10-31 Yamanouchi Europ Bv FORMAS DE DOSIFICACION ORAL CONTENIENDO UN ANTIBIOTICO DE beta -LACTAMA.
EP0781774B1 (en) * 1995-12-08 2002-07-31 Takeda Chemical Industries, Ltd. Prolactin production inhibitory agents
CA2250895A1 (en) * 1996-04-26 1997-11-06 Takeda Chemical Industries, Ltd. Thienopyridine derivatives, their production and use
US6313301B1 (en) * 1997-08-13 2001-11-06 Takeda Chemical Industries, Ltd. Thienopyridine derivatives, their intermediates and production thereof
AU5026599A (en) * 1998-07-23 2000-02-14 Novo Nordisk A/S A wet granulation method for preparing a stable pharmaceutical formulation
WO2001078780A1 (en) * 2000-04-13 2001-10-25 Takeda Chemical Industries, Ltd. Preventives/remedies for alzheimer's disease

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995022981A1 (en) * 1994-02-24 1995-08-31 Nippon Chemiphar Co., Ltd. Oral synthetic peptide preparation
WO1997040846A1 (en) * 1996-04-30 1997-11-06 Takeda Chemical Industries, Ltd. COMBINED USE OF GnRH AGONIST AND ANTAGONIST
JPH1045619A (ja) * 1996-07-31 1998-02-17 Kaken Pharmaceut Co Ltd 成長ホルモン分泌促進ペプチド含有経口製剤
WO2000000493A1 (en) * 1998-06-26 2000-01-06 Takeda Chemical Industries, Ltd. Thienopyridine compounds, their production and use
WO2000056739A1 (en) * 1999-03-24 2000-09-28 Takeda Chemical Industries, Ltd. Thienopyrimidine compounds, their production and use
WO2001012193A1 (en) * 1999-08-16 2001-02-22 Schering Aktiengesellschaft Pharmaceutical agent comprising a benzamide derivative as active ingredient

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1319409A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003064429A1 (en) * 2002-01-30 2003-08-07 Takeda Chemical Industries, Ltd. Thienopyrimidines, process for preparing the same and use thereof

Also Published As

Publication number Publication date
EP1319409A4 (en) 2006-05-03
EP1319409A1 (en) 2003-06-18
AU2001288102A1 (en) 2002-04-02
CA2423329A1 (en) 2003-03-20
US20040034039A1 (en) 2004-02-19

Similar Documents

Publication Publication Date Title
CA2322315A1 (en) Fast disintegrating tablets
NZ512692A (en) Sulphoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
ZA994470B (en) Use of a polymer of acrylic type as a disintegration agent.
EP1334728A3 (en) Antithrombotic agents
HUP1300117A2 (en) Pharmaceutical formulations for dry powder inhalers in the form of hard pellets
MXPA03005893A (es) Proteccion, restauracion, y mejora de celulas, tejidos y organos que responden a la eritropoyetina.
WO2002019981A3 (en) Cosmetic and pharmaceutical composition comprising chelating/sequestering agents and their cosmetic and dermatological use
ZA200305315B (en) Aqueous gel comprising a gelling agent such as kappa carrageenan and at least 85% water.
MY135183A (en) Rapidly disintegrating methylcellulose tablets
HUP0302508A3 (en) Pyridazinones and triazinones and their use as active ingredients of pharmaceutical compositions
WO2002024230A1 (en) Solid preparations
ATE201714T1 (de) Sprengmittelgranulat enthaltende waschmitteltabletten
WO2002056881A8 (fr) Comprimes de fenofibrate
AU2002258002A1 (en) A process for the preparation of tablets from pharmaceutically active substances having unfavourable tabletting properties with a granulating liquid comprising microcrystalline cellulose
AU2001232348A1 (en) Sustained release preparations of physiologically active compound hardly solublein water and production process and use of the same
CA2390092A1 (en) Solid dispersion pharmaceutical formulations
EP0972825A3 (en) Pellet formulations
AU3706999A (en) Controlled release tablet produced from linear water-insoluble polysaccharides
ATE262318T1 (de) Eine wasserlösliche verbindung und cellulose enhaltende granulate
CA2411685A1 (en) Optimised pellet formulations
AU2663800A (en) Use of natural substances to prevent the leaching of agrochemical active ingredients
JPH1045619A5 (ja)
WO2002072064A3 (en) Granular composition comprising an active compound and a cellulose ether and the use thereof
WO2001030324A3 (de) Verwendung von acetylsalicylsäure sowie zubereitung zur behandlung von prostatahyperplasie
WO2005009395A3 (en) Cellulosic fiber containing composition

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001967797

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2423329

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2001967797

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10380725

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP